Physician profile
Brandon M Roscoe
NPI 1639394034
$4,496.79
in general payments reported to CMS, 2019-2025
48 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $1,086 · 2021: $351 · 2022: $510 · 2023: $293 · 2024: $300 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $667.25 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $389.42 | 2019-2020 | |
| Abbvie INC. | $319.07 | 2021-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $315.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $270.56 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Medtronic, INC. | $214.92 | 2021-2022 | |
| Abbott Laboratories | $178.57 | 2021-2024 | Proclaim, Infinity, Freestyle Libre 3 |
| Allergan, INC. | $167.32 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $162.09 | 2019-2023 | Eliquis |
| Amarin Pharma, INC. | $148.65 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $146.13 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $116.73 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $108.45 | 2019 | |
| Ucb, INC. | $102.97 | 2019-2020 | |
| Indivior INC. | $90.02 | 2025 | Sublocade |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Roscoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.